Home  /  Resource Library  /  Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group

Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group

Results of a study investigating Obinutuzumab combined with chlormabucil for first line treatment of CLL.